<?xml version="1.0" encoding="UTF-8"?>
<p id="p0200">These mechanisms may account for immunomodulation of the inflammatory response in COVID-19 secondary to CP administration. As showed above, recent reports suggest the production of antiphospholipid antibodies in patients with COVID-19 together with an antiphospholipid-like syndrome [
 <xref rid="bb0330" ref-type="bibr">66</xref>], and the regulation of this cascade could be critical to avoid deleterious outcomes in these group of patients (
 <italic>i.e.</italic>, thrombosis, disseminated intravascular coagulopathy).
</p>
